(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ...

(Alliance News) - Grit Real Estate Income Group Ltd on Tuesday said it seeks to recalibrate its capital structure as annual net asset value declined amid "persistent macroeconomic headwinds". Shares ...

PureTech has promoted Sven Dethlefs, who has been involved in the drug's development over the past year, to lead Celea. Dethlefs is the ex-chief executive of North America at Teva Pharmaceuticals ...

(Alliance News) - Solvonis Therapeutics PLC on Tuesday reported positive results from pre-clinical screening of a therapy for post-traumatic stress disorder. Shares in the London-based pharmaceutical ...

The FTSE 100 index closed up 18.10 points, 0.2%, at 9,147.81. The FTSE 250 ended 46.80 points lower, 0.2%, at 21,842.69, while the AIM All-Share finished up 1.06 points, 0.1%, at 759.27.

(Alliance News) - Primary Health Properties PLC on Monday declared its revised offer for peer Assura PLC as unconditional, effectively taking "significant" control of the Altrincham, England-based ...

(Alliance News) - Sareum Holdings PLC on Tuesday reported a strategic collaboration with AI-driven drug discovery firm, Receptor.AI, as it looks to accelerate the identification of high-potential ...

Entain allocated GBP47.7 million to the penalty in the first half of 2025. The provision combined with other "separately disclosed items", such as GBP131.0 million in amortisation costs from acquired ...

Rome Resources also said drill hole MADD032 encountered a 13-metre copper intercept with a maximum grade of 13%, and nine metres of tin "within a higher-grade, 13 metres wide zinc zone".

(Alliance News) - t42 IoT Tracking Solutions PLC on Tuesday said it has received orders worth more than USD2.5 million from Contguard Ltd, and has agreed to extend its existing USD1.3 million loan.

(Alliance News) - Spirax Group PLC on Tuesday said it expects second half organic sales growth to accelerate after reporting six-month results ahead of expectations.

(Alliance News) - Polarean Imaging PLC on Tuesday said it has submitted a new phase 3 clinical trial protocol to the US Food & Drug Administration, to support an expanded remit for Xenoview.